Hospira, Inc., provides injectable pharmaceutical drugs and infusion technologies that it develops, manufactures, distributes, and markets worldwide. The Companys portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The Company conducts operations worldwide and is managed in three segments: the Americas (such as the United States, Canada, and Latin America); Europe, the Middle East, and Africa (EMEA); and the Asia Pacific (APAC) (such as Asia, Japan, Australia, and New Zealand).

Official website: www.hospira.com